1. Scrip
  2. >>New Products

Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Approvals Near For Four New Drugs, One New Indication

 
• By Mandy Jackson

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

Office building at Lilly's Indianapolis HQ
Lilly's donanemab setback still could result in a win with positive Phase III data in Q2 • Source: Shutterstock

The theme for Eli Lilly and Company this year is “five-plus-five” as it prepares for five launches – four new medicines and a new obesity indication for diabetes therapy Mounjaro (tirzepatide) – and takes five candidates into Phase III trials. The company will have to remain focused on execution across multiple therapeutic areas, but chief scientific and medical officer Daniel Skovronsky and president of Lilly Diabetes Michael Mason said they believe their teams are up to the task, and that the existing experience in diabetes provides a strong base.

However, the week after Scrip spoke with Skovronsky, who is also president of Lilly Research Laboratories, and Mason at the J.P. Morgan Healthcare Conference in San Francisco, Lilly’s first anticipated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.